iPSC-derived trimodal T cells engineered with CAR, TCR, and hnCD16 modalities can overcome antigen escape in heterogeneous tumorsBi-Huei Yang(Fate Therapeutics (United States)), Bahram Valamehr(Fate Therapeutics (United States))Cell Reports MedicineJune 19, 202510.1016/j.xcrm.2025.102195Cited by 3SaveCiteExport RISWatch citationsRelated PapersA chimeric antigen receptor uniquely recognizing MICA/B stress proteins provides an effective approach to target solid tumors|Med|2023|25